These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19897207)

  • 1. Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective.
    Guy B
    J Comp Pathol; 2010 Jan; 142 Suppl 1():S133-7. PubMed ID: 19897207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine protocols for enhanced immunogenicity of exogenous antigens.
    Heit A; Busch DH; Wagner H; Schmitz F
    Int J Med Microbiol; 2008 Jan; 298(1-2):27-32. PubMed ID: 17888726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New understanding of immunological mechanisms.
    Saalmüller A
    Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction and direction of immune responses by vaccine adjuvants.
    Schijns VE
    Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related changes in immunity: implications for vaccination in the elderly.
    Kovaiou RD; Herndler-Brandstetter D; Grubeck-Loebenstein B
    Expert Rev Mol Med; 2007 Feb; 9(3):1-17. PubMed ID: 17266794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.
    Sexton A; Whitney PG; Chong SF; Zelikin AN; Johnston AP; De Rose R; Brooks AG; Caruso F; Kent SJ
    ACS Nano; 2009 Nov; 3(11):3391-400. PubMed ID: 19824668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines for the elderly.
    Weinberger B; Grubeck-Loebenstein B
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():100-8. PubMed ID: 22862783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.
    Mattner F; Fleitmann JK; Lingnau K; Schmidt W; Egyed A; Fritz J; Zauner W; Wittmann B; Gorny I; Berger M; Kirlappos H; Otava A; Birnstiel ML; Buschle M
    Cancer Res; 2002 Mar; 62(5):1477-80. PubMed ID: 11888923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the requirement of antigen-presenting cells for long-term growth among cytomegalovirus-specific Th clonotypes.
    Santamaria P; Lewis C; Barbosa JJ
    Eur J Immunol; 1993 Nov; 23(11):2972-9. PubMed ID: 8223874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcutaneous and intradermal vaccination.
    Combadiere B; Liard C
    Hum Vaccin; 2011 Aug; 7(8):811-27. PubMed ID: 21817854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
    Gupta RK; Chang AC; Siber GR
    Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines.
    Schweighoffer T; Schmidt W; Buschle M; Birnstiel ML
    Gene Ther; 1996 Sep; 3(9):819-24. PubMed ID: 8875231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.
    Rasmussen IB; Lunde E; Michaelsen TE; Bogen B; Sandlie I
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10296-301. PubMed ID: 11517321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
    Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
    J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.